Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Brainstorm Cell Therapeutics Inc    

News SummaryMost relevantAll newsSector newsTweets

Brainstorm Cell Therapeutics Inc : BrainStorm Announces CEO Interview with the Wall Street Analyst

share with twitter share with LinkedIn share with facebook
share via e-mail
05/23/2013 | 05:03pm CET

BrainStorm Announces CEO Interview with the Wall Street Analyst

New York, NY and Petach Tikvah, Israel, May 23, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that The Wall Street Analyst conducted an audio interview yesterday with the Company's Chief Executive Officer, Alon Natanson. The interview can be heard on The Wall Street Analyst website at the following link: http://thewallstreetanalysts.com/brainstorm-cell-therapeutics-otcqbbcli-ceo-interview.

Topics discussed by Mr. Natanson include an update on the Company's NurOwn™ stem cell technology and its use in current and upcoming clinical trial activities. Specifically, Mr. Natanson discussed the very encouraging observations in the Company's recently completed Phase I/II trial, advances in the ongoing Phase IIa clinical trial and plans for the upcoming Phase II trial, expected to begin later this year in the U.S. at sites including Massachusetts General Hospital, UMass Hospital and the Mayo Clinic.

During the interview Mr. Natanson commented, "As far as companies in this field go, I think we've progressed more quickly than anyone, having successfully completed a Phase I trial in only a year and a half, and moved ahead immediately to Phase II, which should conclude later this year. To achieve all this in only 2 ½ years is extremely fast. We hope to run our upcoming US trial at an equally fast pace, as we feel we are in a race to beat this disease and get our product to the market as quickly as possible."

About The Wall Street Analyst

The Wall Street Analyst conducts unbiased, unfiltered and candid interviews with management of publicly traded companies to unlock possible investment opportunities before the rest of the market discovers them. The WSA's staff of writers, analysts, publishers, producers, market researchers and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock and its audience consists of retail and institutional investors, analysts, fund managers and members of the financial press. For more information, visit www.thewallstreetanalysts.com.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.


BrainStorm Cell Therapeutics Inc. LifeSci Advisors, LLC

Mr. Alon Natanson, CEO Michael Rice, Founding Partner

Phone: +972-3-9236384 Phone: 646-597-6979

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
01/04 BRAINSTORM CELL THERAPEUTICS INC. : Other Events (form 8-K)
2017 BRAINSTORM CELL THERAPEUTICS : to Present at the 10th Annual Biotech Showcase
2017 BRAINSTORM CELL THERAPEUTICS INC. : Submission of Matters to a Vote of Security ..
2017 BRAINSTORM STRENGTHENS EXECUTIVE TEA : Appoints Eyal Rubin as Chief Financial Of..
2017 BRAINSTORM CELL THERAPEUTICS INC. (N : BCLI) Files An 8-K Entry into a Material ..
2017 BRAINSTORM STRENGTHENS EXECUTIVE TEA : Appoints Eyal Rubin as Chief Financial Of..
2017 BRAINSTORM CELL THERAPEUTICS : Expands Its Patent Portfolio to Include a New US ..
2017 BRAINSTORM STRENGTHENS EXECUTIVE TEA : Appoints Eyal Rubin as Chief Financial Of..
2017 BRAINSTORM CELL THERAPEUTICS : Enrolls First Patients in Phase 3 Trial of NurOwn..
More news
Financials ($)
Sales 2017 -
EBIT 2017 -10,8 M
Net income 2017 -10,8 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 0
Capi. / Sales 2018 -
Capitalization 68,0 M
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 9,00 $
Spread / Average Target 149%
EPS Revisions
Chaim Lebovits President & Chief Executive Officer
Irit Arbel Chairman
Ralph Z. Kern Chief Operating & Medical Officer
Eyal Rubin Chief Financial Officer & Treasurer
Yael Gothelf Vice President-Scientific & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%32 824
LONZA GROUP2.92%20 968